Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Allelix reports thrombospondin-derived antihemorrhagic peptide

Dec. 11, 1996

New thrombin inhibitors under study at Merck & Co.

Dec. 9, 1996

Vascular Therapeutics licenses Recordati compound

Dec. 4, 1996

Merck reveals new thrombin inhibitor series

Dec. 3, 1996

3DP seeks partners for protease inhibitor discovery program

Nov. 29, 1996

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Nov. 28, 1996

Potent, orally active antiplatelet agent discovered by Merck & Co.

Nov. 28, 1996

Natural antiplatelet agent discovered at Kitasato Institute

Nov. 28, 1996

RESTORE trial results presented at AHA meeting

Nov. 22, 1996

New market introduction for ReoPro

Nov. 22, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...